ARM’s three-part white paper series discusses innovative financing models for cell and gene therapies.
Gene and cell therapies are designed to durably and even permanently address the underlying cause of a disease. They may be given in just a few administrations, or even a single dose. While these therapies can provide significant direct and indirect savings in medical costs over time, their potentially high upfront cost can create a significant burden on existing reimbursement systems. While reimbursement systems have begun to change to accommodate these new treatments, they still have a way to go to catch up with the immense value provided by advanced therapies.
ARM’s three-part white paper series describes the challenges durable and potentially curative therapies poise to existing reimbursement paradigms in the U.S.; identifies alternative payment models that could address the challenges; and discusses how to overcome barriers to the implementation of these innovative payment models.
